New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
07:38 EDTSRPTSarepta reports Q2 EPS (61c), consensus (76c)
Reports Q2 revenue $2.6M, consensus $4.3M. The company now expects that Non-GAAP loss from operations will range from $135M-$135M, as compared with its previous guidance of $110M-$120M. In addition, The company is anticipating capital investments of approximately $25M for the remainder of 2014 in connection with its manufacturing facility in Andover and 2015 inventory commitments.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
10:20 EDTSRPTNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
September 4, 2014
13:17 EDTSRPTSarepta rises after FDA seeks comment on proposed DMD drug guidance
Subscribe for More Information
12:54 EDTSRPTSarepta strength attributed to circulation of DMD guidance document
Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use